Bevacizumab for malignant gliomas

current indications, mechanisms of action and resistance, and markers of response

Ryota Tamura, Toshihide Tanaka, Keisuke Miyake, Kazunari Yoshida, Hikaru Sasaki

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) is an attractive target of antiangiogenic therapy in glioblastomas. Bevacizumab (Bev), a humanized anti-VEGF antibody, is associated with the improvement of progression-free survival and performance status in patients with glioblastoma. However, randomized trials uniformly suggest that these favorable clinical effects of Bev do not translate into an overall survival benefit. The mechanisms of action of Bev appear to include the inhibition of tumor angiogenesis, as well as indirect effects such as the depletion of niches for glioma stem cells and stimulation of antitumor immunity. Although several molecules/pathways have been reported to mediate adaptation and resistance to Bev, including the activation of alternative pro-angiogenic pathways, the resistance mechanisms have not been fully elucidated; for example, the mechanism that reinduces tumor hypoxia remains unclarified. The identification of imaging characteristics or biomarkers predicting the response to Bev, as well as the better understanding of the mechanisms of action and resistance, is crucial to improve the overall clinical outcome and optimize individual therapy. In this article, the authors review the results of important clinical trials/studies, the current understanding of the mechanisms of action and resistance, and the knowledge of imaging characteristics and biomarkers predicting the response to Bev.

Original languageEnglish
Pages (from-to)1-16
Number of pages16
JournalBrain Tumor Pathology
DOIs
Publication statusAccepted/In press - 2017 Apr 6

Fingerprint

Glioma
Glioblastoma
Vascular Endothelial Growth Factor A
Biomarkers
Stem Cell Niche
Disease-Free Survival
Bevacizumab
Immunity
Clinical Trials
Survival
Antibodies
Therapeutics
Neoplasms

Keywords

  • Bevacizumab
  • Glioblastoma
  • Glioma stem cell
  • Hypoxia
  • Immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Bevacizumab for malignant gliomas : current indications, mechanisms of action and resistance, and markers of response. / Tamura, Ryota; Tanaka, Toshihide; Miyake, Keisuke; Yoshida, Kazunari; Sasaki, Hikaru.

In: Brain Tumor Pathology, 06.04.2017, p. 1-16.

Research output: Contribution to journalArticle

@article{107f7572d37c4f48a989884ffc73742c,
title = "Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response",
abstract = "Vascular endothelial growth factor (VEGF) is an attractive target of antiangiogenic therapy in glioblastomas. Bevacizumab (Bev), a humanized anti-VEGF antibody, is associated with the improvement of progression-free survival and performance status in patients with glioblastoma. However, randomized trials uniformly suggest that these favorable clinical effects of Bev do not translate into an overall survival benefit. The mechanisms of action of Bev appear to include the inhibition of tumor angiogenesis, as well as indirect effects such as the depletion of niches for glioma stem cells and stimulation of antitumor immunity. Although several molecules/pathways have been reported to mediate adaptation and resistance to Bev, including the activation of alternative pro-angiogenic pathways, the resistance mechanisms have not been fully elucidated; for example, the mechanism that reinduces tumor hypoxia remains unclarified. The identification of imaging characteristics or biomarkers predicting the response to Bev, as well as the better understanding of the mechanisms of action and resistance, is crucial to improve the overall clinical outcome and optimize individual therapy. In this article, the authors review the results of important clinical trials/studies, the current understanding of the mechanisms of action and resistance, and the knowledge of imaging characteristics and biomarkers predicting the response to Bev.",
keywords = "Bevacizumab, Glioblastoma, Glioma stem cell, Hypoxia, Immunotherapy",
author = "Ryota Tamura and Toshihide Tanaka and Keisuke Miyake and Kazunari Yoshida and Hikaru Sasaki",
year = "2017",
month = "4",
day = "6",
doi = "10.1007/s10014-017-0284-x",
language = "English",
pages = "1--16",
journal = "Brain Tumor Pathology",
issn = "1433-7398",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Bevacizumab for malignant gliomas

T2 - current indications, mechanisms of action and resistance, and markers of response

AU - Tamura, Ryota

AU - Tanaka, Toshihide

AU - Miyake, Keisuke

AU - Yoshida, Kazunari

AU - Sasaki, Hikaru

PY - 2017/4/6

Y1 - 2017/4/6

N2 - Vascular endothelial growth factor (VEGF) is an attractive target of antiangiogenic therapy in glioblastomas. Bevacizumab (Bev), a humanized anti-VEGF antibody, is associated with the improvement of progression-free survival and performance status in patients with glioblastoma. However, randomized trials uniformly suggest that these favorable clinical effects of Bev do not translate into an overall survival benefit. The mechanisms of action of Bev appear to include the inhibition of tumor angiogenesis, as well as indirect effects such as the depletion of niches for glioma stem cells and stimulation of antitumor immunity. Although several molecules/pathways have been reported to mediate adaptation and resistance to Bev, including the activation of alternative pro-angiogenic pathways, the resistance mechanisms have not been fully elucidated; for example, the mechanism that reinduces tumor hypoxia remains unclarified. The identification of imaging characteristics or biomarkers predicting the response to Bev, as well as the better understanding of the mechanisms of action and resistance, is crucial to improve the overall clinical outcome and optimize individual therapy. In this article, the authors review the results of important clinical trials/studies, the current understanding of the mechanisms of action and resistance, and the knowledge of imaging characteristics and biomarkers predicting the response to Bev.

AB - Vascular endothelial growth factor (VEGF) is an attractive target of antiangiogenic therapy in glioblastomas. Bevacizumab (Bev), a humanized anti-VEGF antibody, is associated with the improvement of progression-free survival and performance status in patients with glioblastoma. However, randomized trials uniformly suggest that these favorable clinical effects of Bev do not translate into an overall survival benefit. The mechanisms of action of Bev appear to include the inhibition of tumor angiogenesis, as well as indirect effects such as the depletion of niches for glioma stem cells and stimulation of antitumor immunity. Although several molecules/pathways have been reported to mediate adaptation and resistance to Bev, including the activation of alternative pro-angiogenic pathways, the resistance mechanisms have not been fully elucidated; for example, the mechanism that reinduces tumor hypoxia remains unclarified. The identification of imaging characteristics or biomarkers predicting the response to Bev, as well as the better understanding of the mechanisms of action and resistance, is crucial to improve the overall clinical outcome and optimize individual therapy. In this article, the authors review the results of important clinical trials/studies, the current understanding of the mechanisms of action and resistance, and the knowledge of imaging characteristics and biomarkers predicting the response to Bev.

KW - Bevacizumab

KW - Glioblastoma

KW - Glioma stem cell

KW - Hypoxia

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85017132036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017132036&partnerID=8YFLogxK

U2 - 10.1007/s10014-017-0284-x

DO - 10.1007/s10014-017-0284-x

M3 - Article

SP - 1

EP - 16

JO - Brain Tumor Pathology

JF - Brain Tumor Pathology

SN - 1433-7398

ER -